Alzheimer’s Research & Therapy
Print ISSN
1758-9193
e-ISSN
1758-9193
Country
GB
Language
EN
Founded
2009
Journal Info
Publisher
BMC
50
Articles
0
Volumes
Published Works
Recent Articles
Biomarkers in Alzheimer’s disease: role in early and differential diagnosis and recognition of atypical variants
Bruno Dubois, Christine A. F. Von Arnim, Nerida Burnie
Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice
Matthew J. Simon, Marie Xun Wang, Ozama Ismail
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
Eric McDade, Jeffrey L. Cummings, Shobha Dhadda
Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer’s disease dementia: a systematic review
Sergio Grueso, Raquel Viejo-Sobera
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
Chad J. Swanson, Yong Zhang, Shobha Dhadda
Randomized crossover trial of a modified ketogenic diet in Alzheimer’s disease
Matthew C. L. Phillips, Laura Deprez, Grace M. N. Mortimer
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Claudia Cicognola, Shorena Janelidze, Joakim Hertze
Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach
Alzheimer's Disease Neuroimaging Initiative, Sarah K. Royse, Davneet Singh Minhas
Cognitive impact of COVID-19: looking beyond the short term
James Scott Miners, Patrick G. Kehoe, Seth Love
Immediate and long-term consequences of COVID-19 infections for the development of neurological disease
Michael Thomas Heneka, Douglas Taylor Golenbock, Eicke Latz
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
Martin Tolar, Susan R. Abushakra, John A. Hey
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
the Synaptic Health Endpoints Working Group, Martí Colom‐Cadena, Tara L. Spires‐Jones